Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Beta cells in the islets of Langerhans release insulin in two phases. The first-phase release is rapidly triggered in response to increased blood glucose levels, and lasts about 10 minutes. The second phase is a sustained, slow release of newly formed vesicles triggered independently of sugar, peaking in 2 to 3 hours. The two phases of the insulin release suggest that insulin granules are present in diverse stated populations or "pools". During the first phase of insulin exocytosis, most of the granules predispose for exocytosis are released after the calcium internalization. This pool is known as Readily Releasable Pool (RRP). The RRP granules represent 0.3-0.7% of the total insulin-containing granule population, and they are found immediately adjacent to the plasma membrane. During the second phase of exocytosis, insulin granules require mobilization of granules to the plasma membrane and a previous preparation to undergo their release. Thus, the second phase of insulin release is governed by the rate at which granules get ready for release. This pool is known as a Reserve Pool (RP). The RP is released slower than the RRP (RRP: 18 granules/min; RP: 6 granules/min). Reduced first-phase insulin release may be the earliest detectable beta cell defect predicting onset of type 2 diabetes. First-phase release and insulin sensitivity are independent predictors of diabetes. The description of first phase release is as follows:
The advantage of diamorphine over morphine is that diamorphine is more fat soluble and therefore more potent by injection, so smaller doses of it are needed for the same effect on pain. Both of these factors are advantageous if giving high doses of opioids via the subcutaneous route, which is often necessary for palliative care. It is also used in the palliative management of bone fractures and other trauma, especially in children. In the trauma context, it is primarily given by nose in hospital; although a prepared nasal spray is available, it has traditionally been made by the attending physician, generally from the same "dry" ampoules as used for injection. In children, Ayendi nasal spray is available at 720 micrograms and 1600 micrograms per 50 microlitres actuation of the spray, which may be preferable as a non-invasive alternative in pediatric care, avoiding the fear of injection in children.
Different porphyroblasts like garnet and quartz are often formed during metamorphism in different ranges of P-T. Monazite grains are often found as inclusion in porphyroblasts. Since the host mineral monazite is quite thermally resistant, these inclusions are protected from age resetting, even with a prolonged exposure at temperature higher than 800 °C, this enables us to restrict an upper limit of the age of the porphyroblasts, and thus the associated metamorphic events. For example, a metamorphic rock in the Neil Bay area of northern Saskatchewan underwent high grade (high P/T) metamorphism followed by exhumation (uplift). The porphyroblast of garnet was formed during high grade metamorphism while the porphyroblast of cordierite was formed during subsequent exhumation. Both porphyroblasts contain monazite inclusions which were dated at 1910 Ma and 1840 Ma, respectively. And matrix monazite is dated 1800 Ma. Thus, it is interpreted that high grade metamorphism occurred after 1910 Ma and before 1840 Ma, while exhumation occurred after 1840 Ma, and the final annealing (cooling and coarsening of minerals) happened at 1800 Ma. Within the same setting as above, monazite inclusions in garnet maybe either younger than, older than or have similar ages with the matrix monazite. Both of them may even have a wide range of ages with no systematic distribution. These scenarios are interpreted to represent different metamorphic paths and conditions, giving varying or complex sequences of metamorphic reactions.
==== Distribution ==== Following a 600 mg oral dose, peak plasma concentrations (Cmax) are achieved in approximately 2 hours under fasting conditions and 4 hours under non-fasting conditions. The presence of food alters absorption; the bioavailability of the tablet formulation decreases by 21–23% under moderate to high-fat conditions relative to fasting conditions. Ritonavir is highly bound (98–99%) to human serum proteins, primarily binding to serum albumin and α1-acid glycoprotein over a concentration range of 0.01 to 30 µg/mL. This extensive protein binding attenuates its free antiviral activity in vitro by approximately 20-fold. The drug exhibits a volume of distribution (Vd) of 0.41 ± 0.25 L/kg.
=== β+ decay and electron capture === In 1934, Frédéric and Irène Joliot-Curie bombarded aluminium with alpha particles to effect the nuclear reaction 42He + 2713Al → 3015P + 10n, and observed that the product isotope 3015P emits a positron identical to those found in cosmic rays (discovered by Carl David Anderson in 1932). This was the first example of β+ decay (positron emission), which they termed artificial radioactivity since 3015P is a short-lived nuclide which does not exist in nature. In recognition of their discovery, the couple were awarded the Nobel Prize in Chemistry in 1935. The theory of electron capture was first discussed by Gian-Carlo Wick in a 1934 paper, and then developed by Hideki Yukawa and others. K-electron capture was first observed in 1937 by Luis Alvarez, in the nuclide 48V. Alvarez went on to study electron capture in 67Ga and other nuclides.
Sources: en.wikipedia.org
==== Other potential causes ==== Additional conditions that may present with similar clinical features include polymyalgia rheumatica, diabetic lumbosacral plexopathy, spinal stenosis, and non-inflammatory pain syndromes such as fibromyalgia.
=== Available forms === Pure lorazepam is an almost white powder that is nearly insoluble in water and oil. In medicinal form, it is mainly available as tablets and a solution for injection, but, in some locations, it is also available as a skin patch, an oral solution, and a sublingual tablet. Lorazepam injectable solution is administered either by deep intramuscular injection or by intravenous injection. The injectable solution comes in 1 mL ampoules containing 2 or 4 mg of lorazepam. The solvents used are polyethylene glycol 400 and propylene glycol. As a preservative, the injectable solution contains benzyl alcohol. Toxicity from propylene glycol has been reported in the case of a person receiving a continuous lorazepam infusion. Topical formulations of lorazepam, while sometimes used as a treatment for nausea, especially in people in hospice, has been advised against by the American Academy of Hospice and Palliative Medicine for this purpose as it has not been proven effective.
The above reactions are balanced if Pi represents the H2PO4− ion, ADP and GDP the ADP2− and GDP2− ions, respectively, and ATP and GTP the ATP3− and GTP3− ions, respectively. The total number of ATP molecules obtained after complete oxidation of one glucose in glycolysis, citric acid cycle, and oxidative phosphorylation is estimated to be between 30 and 38.
=== Numerical solution techniques === Distinctions between conforming and non-conforming contact do not have to be made when numerical solution schemes are employed to solve contact problems. These methods do not rely on further assumptions within the solution process since they base solely on the general formulation of the underlying equations. Besides the standard equations describing the deformation and motion of bodies two additional inequalities can be formulated. The first simply restricts the motion and deformation of the bodies by the assumption that no penetration can occur. Hence the gap
Sources: en.wikipedia.org
Sympathomimetics (catecholaminergics)—e.g. amphetamine, methamphetamine, cocaine, methylphenidate, ephedrine, pseudoephedrine Entactogens (serotonergics, primarily phenethylamines)—e.g. MDMA (which is also an amphetamine) Eugeroics, e.g. modafinil Others arecoline (found in Areca catechu) caffeine (found in Coffea spp.) nicotine (found in Nicotiana spp.) rauwolscine (found in Rauvolfia serpentina) yohimbine (Procomil; a tryptamine alkaloid found in Pausinystalia johimbe)
== Biography == Vincent du Vigneaud was born in Chicago in 1901. Of French descent, he was the son of inventor and mechanic Alfred du Vigneaud and Mary Theresa. He studied at the Schurz High School and completed secondary education in 1918. His interest in sulfur began when he entered high school and his new friends invited him to run chemical experiments on explosives using sulfur. During World War I, senior students were made to work on farms, and du Vigneaud worked near Caledonia, Illinois. There he became an expert in milking cows, which inspired him to become a farmer. However, his elder sister, Beatrice, persuaded him to take up chemistry at the University of Illinois at Urbana-Champaign, after which he enrolled in the chemical engineering course. He later recalled: I found during the first year that it was chemistry rather than engineering that appealed to me most. I switched to a major in chemistry, since I was deeply impressed by the senior student's work, especially in organic chemistry. I also found that I was most interested in those aspects of organic chemistry that had to do with medical substances and began to develop an interest in biochemistry.His interest was aroused by lectures of Carl Shipp Marvel and Howard B. Lewis, whom he remembered as being 'extremely enthusiastic about sulfur." With little support from the family, he found odd jobs to support himself. After receiving his MS in 1924 he joined DuPont. He married Zella Zon Ford, whom he met on June 12, 1924, while working as a waiter during his university course.
== Side effects == As with other opioids, tolerance and physical and psychological dependence develop with repeated dihydrocodeine use. All opioids can impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving or operating machinery if taken in large doses. Itching and flushing and other effects of blood vessel dilation are also common side-effects, due to histamine release in response to the drug using one or more types of receptors in the CNS or other responses elsewhere in the body. First-generation antihistamines such as tripelennamine (Pyrabenzamine), clemastine (Tavist), hydroxyzine (Atarax), diphenhydramine (Benadryl), cyproheptadine (Periactin), brompheniramine (Dimetapp), chlorphenamine (Chlor-Trimeton), doxylamine (NyQuil) and phenyltoloxamine (Percogesic Original Formula) not only combat the histamine-driven side-effects, but are analgesic-sparing (potentiating) in various degrees. The antihistamine promethazine (Phenergan) may also have a positive effect on hepatic metabolism of dihydrocodeine as it does with codeine. Higher doses of promethazine may interfere with most other opioids with the exception of the pethidine family (Demerol and the like) by this or other unknown mechanisms. As with all drugs, side-effects depend on the person taking the medication. They can range in severity from mild to extreme, from headaches to difficulty breathing. Constipation is the one side-effect of dihydrocodeine and almost all opioids which is near-universal.
Organic insulator: valued for their large surface areas Radiative cooling: Aerogels can aid in thermal emittance at lower cost and environmental impact than other materials. Passive thermal protection: The US Navy evaluated aerogels for use in diver undergarments and by NASA for insulating space suits. Radiators in Cherenkov effect detectors: The ACC system of the Belle detector used aerogels in the Belle experiment at KEKB, because of their low index of refraction, filling the gap between gases and liquids, and their transparency and solid state, making them easier to use than cryogenic liquids or compressed gases. Sensors Sound insulation, on windows or during construction. Tennis rackets: Dunlop Sport uses aerogel in some racquets. Textiles and other flexible materials: "Commercial manufacture of aerogel 'blankets' began around the year 2000, combining silica aerogel and fibrous reinforcement that turns the brittle aerogel into a durable, flexible material. The mechanical and thermal properties of the product may be varied based upon the choice of reinforcing fibers, the aerogel matrix and opacification additives included in the composite." Thermal insulation: fibre-reinforced silica aerogel insulation boards insulation can be about 50% as thick as conventional materials. They are -suited for historic building retrofit,. Aerogel has been added in granular form to skylights for this purpose. Georgia Institute of Technology's 2007 Solar Decathlon House project used an aerogel as an insulator in its translucent roof. Transmission tunnel of the Chevrolet Corvette (C7).
Lay the foundations to enable AI: securing world-class computing and data infrastructure, access to talent, and an appropriate regulatory environment. Key commitments include expanding the AI Research Resource (AIRR) by at least 20 times by 2030, establishing "AI Growth Zones" (AIGZs) to accelerate the build-out of AI data centres through streamlined planning and power provisioning, and developing a sovereign AI compute capability. Change lives by embracing AI: driving rapid AI adoption in the public sector, including in the National Health Service, education, and government administration, to improve public services and boost productivity. Secure our future with homegrown AI: positioning the UK as a partner of choice for frontier AI developers and building domestic AI companies that operate at multiple layers of the "AI stack", to ensure the UK benefits economically and has influence over the values and governance of future AI systems. The government projected that AI adoption could grow the UK economy by an additional £400 billion by 2030 and committed to a £2 billion investment in AI infrastructure. The UK government has proposed a plan to boost the country's AI infrastructure and expand its use in public services, with the UK Prime Minister Keir Starmer saying that the country would become one of the "AI superpowers".
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.